GOSS
HEALTHCAREGossamer Bio Inc
AI Insight
What's Moving GOSS Today?
No stock-specific AI insight has been generated for GOSS yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$0.14$3.87
$0.17
Fundamentals
Market Cap$80M
P/E Ratio—
EPS$-0.79
Dividend Yield—
Dividend / Share—
ROE-783.0%
Profit Margin—
Debt / Equity—
Trading
Volume13.4M
Avg Volume (10D)—
Shares Outstanding488.8M
GOSS News
42 articles- Gossamer Bio (GOSS) Stock Faces Mixed Analyst Target Changes On Funding RiskYahoo Finance·Jun 18, 2026
- Gossamer Bio Inc (GOSS) Valuation: PE, PB & Fair Value AnalysisTradingKey·Jun 18, 2026
- Gossamer Bio Inc (GOSS) Q1 2026 Earnings Call Highlights: Strategic Debt Reduction and ...Yahoo Finance·Jun 17, 2026
- Gossamer Bio, Inc. Announces Final Tender Results for Exchange Offer and Consent Solicitation with Respect to Existing Convertible NotesYahoo Finance·Jun 17, 2026
- Harbour BioMed Appoints Dr. Luisa Salter-Cid as Scientific AdvisorYahoo Finance·Jun 11, 2026
- Gossamer Bio, Inc. Announces Early Tender Results and Early Settlement for Exchange Offer and Consent Solicitation with Respect to Existing Convertible NotesYahoo Finance·Jun 3, 2026
- How The Investment Story For Gossamer Bio (GOSS) Is Quietly Shifting Without New Analyst SignalsYahoo Finance·Jun 3, 2026
- Gossamer Bio (NASDAQ: GOSS) extends early tender deadline in major convertible note exchangeStock Titan·Jun 2, 2026
- Gossamer Bio, Inc. Announces Extension of Early Tender Date for Exchange Offer and Consent Solicitation with Respect to Existing Convertible NotesYahoo Finance·Jun 2, 2026
- GOSS Investors Have Opportunity to Lead Gossamer Bio, Inc. Securities Fraud Lawsuit with the Schall Law FirmGlobeNewswire·May 31, 2026
- Gossamer Bio (GOSS) Q1 2026 Earnings TranscriptMotley Fool·May 27, 2026
- Pulmonary Arterial Hypertension Market Outlook Shows Strong Upward Trend at a CAGR of 6.7% During the Study Period (2022-2036) Supported by New Clinical Developments | DelveInsightYahoo Finance·May 25, 2026
- Gossamer Bio Shares Decline After Wider-Than-Expected Q1 Loss Despite Revenue Beat (GOSS)Advfn·May 18, 2026
- Gossamer Bio Q1 Earnings Call HighlightsMarketbeat·May 18, 2026
- Gossamer Bio, Inc. Launches Exchange Offer and Consent Solicitation Intended to Eliminate Over $120 Million of Debt with Existing Noteholder SupportYahoo Finance·May 18, 2026
- Gossamer Bio Announces First Quarter 2026 Financial Results and Provides Business UpdateYahoo Finance·May 18, 2026
- GOSS STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Gossamer Bio, Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit!ACCESS Newswire·May 18, 2026
- Gossamer Bio (GOSS) Reports Q1 Loss, Tops Revenue EstimatesYahoo Finance·May 15, 2026
- Gossamer Bio to Announce First Quarter 2026 Financial Results and Host Conference Call and Webcast on May 18, 2026Yahoo Finance·May 15, 2026
- INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Gossamer Bio, Inc. of Class Action Lawsuit and Upcoming Deadlines - GOSSPR Newswire·May 15, 2026
- Regenxbio (RGNX) Reports Q1 Loss, Lags Revenue EstimatesYahoo Finance·May 14, 2026
- Kura Oncology (KURA) Reports Q1 Loss, Tops Revenue EstimatesYahoo Finance·May 12, 2026
- How The Gossamer Bio (GOSS) Story Is Shifting After The PROSERA Miss And Cash ConcernsYahoo Finance·May 11, 2026
- Intellia Therapeutics, Inc. (NTLA) Reports Q1 Loss, Misses Revenue EstimatesYahoo Finance·May 11, 2026
- CytomX Therapeutics (CTMX) Reports Q1 Loss, Beats Revenue EstimatesYahoo Finance·May 7, 2026
- GOSS Investor Alert: Gossamer Bio Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After CEO Allegedly Concealed PROSERA Placebo Risk: SueWallSt – Company Announcement - FT.comFinancial Times·May 7, 2026
- ROSEN, THE FIRST FILING FIRM, Encourages zSpace Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - ZSPCGlobeNewswire Inc.·Apr 28, 2026
- INVESTOR NOTICE: Gossamer Bio, Inc. (GOSS) Investors with Substantial Losses Have Opportunity to Lead Investor Class Action– Hagens BermanGlobeNewswire Inc.·Apr 28, 2026
- ROSEN, SKILLED INVESTOR COUNSEL, Encourages Gossamer Bio, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – GOSSGlobeNewswire Inc.·Apr 28, 2026
- Bronstein, Gewirtz & Grossman LLC Urges Gossamer Bio, Inc. Investors to Act: Class Action Filed Alleging Investor HarmGlobeNewswire Inc.·Apr 27, 2026
- ROSEN, LEADING INVESTOR COUNSEL, Encourages Gossamer Bio, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – GOSSGlobeNewswire Inc.·Apr 24, 2026
- ROSEN, SKILLED INVESTOR COUNSEL, Encourages zSpace Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - ZSPCGlobeNewswire Inc.·Apr 24, 2026
- Gossamer Bio, Inc. (GOSS) Faces Securities Class Action Amid 80% Drop On Phase 3 PROSERA Trial Failure– Hagens BermanGlobeNewswire Inc.·Apr 23, 2026
- DEADLINE ALERT for PINS, NUAI, GOSS, MEDP: Law Offices of Howard G. Smith Reminds Investors of Opportunity to Lead Securities Fraud Class ActionsGlobeNewswire Inc.·Apr 20, 2026
- Bronstein, Gewirtz & Grossman LLC Urges Gossamer Bio, Inc. Investors to Act: Class Action Filed Alleging Investor HarmGlobeNewswire Inc.·Apr 20, 2026
- Bronstein, Gewirtz & Grossman LLC Urges Aquestive Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor HarmGlobeNewswire Inc.·Apr 16, 2026
- Bronstein, Gewirtz & Grossman LLC Urges Gossamer Bio, Inc. Investors to Act: Class Action Filed Alleging Investor HarmGlobeNewswire Inc.·Apr 16, 2026
- COTY Investor Alert: Coty Inc. Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Company Allegedly Misled on Growth Timeline: Levi & KorsinskyGlobeNewswire Inc.·Apr 13, 2026
- Deadline Alert: Gossamer Bio, Inc. (GOSS) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud LawsuitGlobeNewswire Inc.·Apr 13, 2026
- Interstitial Lung Disease Market to Witness Accelerated Growth at a CAGR of 8.7% During the Forecast Period (2026–2036) Due to the Launch of Emerging Therapies | DelveInsightGlobeNewswire Inc.·Apr 8, 2026
Price Data
Open$0.16
Previous Close$0.16
Day High$0.18
Day Low$0.16
52 Week High$3.87
52 Week Low$0.14
52-Week Range
$0.14$3.87
$0.17
Fundamentals
Market Cap$80M
P/E Ratio—
EPS$-0.79
Dividend Yield—
Dividend / Share—
ROE-783.0%
Profit Margin—
Debt / Equity—
Trading
Volume13.4M
Avg Volume (10D)—
Shares Outstanding488.8M
About Gossamer Bio Inc
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapies in the areas of immunology, inflammation, and oncology diseases in the United States. The company is headquartered in San Diego, California.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeCommon Stock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—